On June 2, 2020 Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, reported that recruiting has begun and the first patient has been enrolled in the Emory University Phase 1 clinical trial of WP1066 for the treatment of brain tumors in children (Press release, Moleculin, JUN 2, 2020, View Source [SID1234560752]). The study is being conducted at the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors. (PRNewsfoto/Moleculin Biotech, Inc.)

WP1066 is the lead molecule in Moleculin’s portfolio of immune stimulators and modulators of transcription. WP1066 has been shown in animal models to both stimulate a natural immune response, while also inhibiting the activated form of STAT3 (p-STAT3), a gene transcription factor that is considered a master regulator of tumor-related activity.

"p-STAT3 has long been considered an ‘undruggable’ target," commented Walter Klemp, Chairman and CEO of Moleculin. "We’ve shown activity in patients with WP1220, one of the other molecules in this portfolio. This trial represents another opportunity to show that p-STAT3 is a viable target. We are honored to be a part of this effort to cure childhood brain tumors."